神经母细胞瘤中18F-间氟苄胍PET显像的病灶分析
研究纳入37例复发或难治性神经母细胞瘤患者的40对18F-MFBG PET与123I-MIBG显像,比较病灶检出。所有123I-MIBG阳性患者18F-MFBG均阳性,30/40对扫描中18F-MFBG显示更多部位,平均病灶数18 vs 12,Curie评分平均11 vs 8。273个18F-MFBG阳性/123I-MIBG阴性病灶中234个随访确认100%真阳性。
要点
- 所有123I-MIBG阳性患者18F-MFBG显像均阳性。
- 30/40对扫描中18F-MFBG显示更多病灶部位。
- 18F-MFBG平均病灶数18 vs 123I-MIBG 12,Curie评分11 vs 8。
核心结论
- 18F-MFBG PET显像较123I-MIBG显像成像更快且病灶检出更优。
- 18F-MFBG在患者水平与123I-MIBG高度一致,并在多数患者中显示更多病灶。
- 18F-MFBG是123I-MIBG有吸引力的替代选择。
研究设计与样本
- 分析37例复发或难治性神经母细胞瘤患者的40对同期18F-MFBG与123I-MIBG扫描。
- 患者静脉注射74.11-465.83 MBq(2.0-12.6 mCi)18F-MFBG,注射后60分钟成像。
- 所有患者在18F-MFBG显像后4周内完成123I-MIBG扫描,期间未接受任何治疗。
- 123I-MIBG扫描包括全身平面显像及胸、腹、盆腔SPECT/CT。
主要发现
- 所有123I-MIBG阳性患者18F-MFBG显像均阳性;2例患者两种扫描均阴性;1例患者18F-MFBG阳性而123I-MIBG阴性。
- 40对扫描中30对18F-MFBG显示更多部位。
- 18F-MFBG平均病灶数18(范围0-61)vs 123I-MIBG平均12(范围0-44),455个病灶一致。
- 18F-MFBG的Curie评分平均11(范围0-25)vs 123I-MIBG平均8(范围0-22)。
- 273个18F-MFBG阳性/123I-MIBG阴性病灶中,30例患者的234个病灶有随访临床和影像评估,100%确认为真阳性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A PET analog of metaiodobenzylguanidine (MIBG)-18F-metafluorobenzylguanidine (18F-MFBG)-allows for rapid same-day imaging. We previously reported on the safety and feasibility of 18F-MFBG PET imaging in patients with neuroendocrine tumors. We now report a comprehensive analysis of lesion detection with 18F-MFBG imaging in patients with neuroblastoma compared with 123I-MIBG imaging. Methods: We analyzed concurrent 18F-MFBG and 123I-MIBG scans in 37 patients (40 paired scans). Patients with relapsed or refractory neuroblastoma were included. Patients received 74.11-465.83 MBq (2.0-12.6 mCi) of 18F-MFBG intravenously, followed by imaging 60 min after injection. All patients had an 123I-MIBG scan within 4 wk of 18F-MFBG imaging without any intervening therapy. 123I-MIBG scans included whole-body planar and SPECT/CT of the chest, abdomen, and pelvis. All detected lesions were noted for each modality. 123I-MIBG and 18F-MFBG findings were evaluated for concordance and discordance. Modified Curie scores were assigned to both 123I-MIBG scans, equivalent scores were ascertained for 18F-MFBG imaging, and scores were then compared. Results: All patients with a positive 123I-MIBG scan had positive 18F-MFBG imaging. In 2 patients, both 123I-MIBG and 18F-MFBG scans were negative. In 1 patient, the 18F-MFBG scan was positive, whereas the 123I-MIBG scan was negative. In 30 of 40 scans, 18F-MFBG showed more sites than did 123I-MIBG. Overall, more lesions were noted on the 18F-MFBG scans (mean, 18; range 0-61) compared with the 123I-MIBG scans (mean, 12; range, 0-44), and 455 lesions were concordant. The Curie score for 18F-MFBG was higher, with an average of 11 (range, 0-25) compared with 8 for 123I-MIBG (range, 0-22). Of the 273 18F-MFBG-positive/123I-MIBG-negative lesions, follow-up clinical and imaging assessment was available for 234 lesions in 30 patients, and 100% of these were confirmed true-positive. Conclusion: 18F-MFBG PET offers faster imaging and superior detection compared with 123I-MIBG imaging. 18F-MFBG had high concordance with 123I-MIBG at the patient level and showed more lesions in most patients. 18F-MFBG is an attractive alternative to 123I-MIBG.
引用
- Pandit-Taskar N, Basu E, Pirasteh A, et al. Lesion Analysis of 18F-Metafluorobenzylguanidine PET Imaging in Neuroblastoma. J Nucl Med. 2025. PMID: 40908121. doi:10.2967/jnumed.125.269833
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。